GlaxoSmithKline: New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and Over for More Than a Decade
April 18, 2024
April 18, 2024
LONDON, England, April 18 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on April 17, 2024:
GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with Shingrix (Recombinant Zoster Vaccine or RZV). The final trial data demonstrate that RZV maintains efficacy against shingles for more than a decade in adu . . .
GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with Shingrix (Recombinant Zoster Vaccine or RZV). The final trial data demonstrate that RZV maintains efficacy against shingles for more than a decade in adu . . .